Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors

Authors
Category Primary study
JournalCancer research. Conference: 107th annual meeting of the american association for cancer research, AACR 2016. United states. Conference start: 20160416. Conference end: 20160420
Year 2016
This article has no abstract
Epistemonikos ID: 697f525a0cf8145a35d55125aa179e3865f4ff26
First added on: Feb 01, 2023